A phase 1/11 trial of IVCG7870, a replication-selective, PSA-targeted oncolytic adenovirus (OAV), for the treatment of hormone-refractory, metastatic prostate cancer

被引：0
|
作者：
Wilding, G
Carducci, M
Yu, DC
Burke, J
Borellini, F
Aimi, J
Working, P
Ando, D
Kirn, D
Small, E
机构：
[1] Univ Wisconsin, Madison, WI 53706 USA
[2] Johns Hopkins Univ, Baltimore, MD 21218 USA
[3] Cell Genesys Inc, San Francisco, CA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3036
引用
收藏
页码：204S / 204S
页数：1
相关论文
共 5 条
  • [1] A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
    Small, Eric J.
    Carducci, Michael A.
    Burke, James M.
    Rodriguez, Ron
    Fong, Lawrence
    van Ummersen, Lynn
    Yu, D. C.
    Aimi, Junko
    Ando, Dale
    Working, Peter
    Kirn, David
    Wilding, George
    MOLECULAR THERAPY, 2006, 14 (01) : 107 - 117
  • [2] Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer
    Miller, AM
    Özenci, V
    Kiessling, R
    Pisa, P
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (04) : 389 - 395
  • [3] Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: A multicenter phase II trial in Japan
    Naito, S.
    Tsukamoto, T.
    Koga, H.
    Harabayashi, T.
    Sumiyoshi, Y.
    Hoshi, S.
    Akaza, H.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (05) : 365 - 372
  • [4] A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
    DeWeese, TL
    van der Poel, H
    Li, SD
    Mikhak, B
    Drew, R
    Goemann, M
    Hamper, U
    DeJong, R
    Detorie, N
    Rodriguez, R
    Haulk, T
    DeMarzo, AM
    Piantadosi, S
    Yu, DC
    Chen, Y
    Henderson, DR
    Carducci, MA
    Nelson, WG
    Simons, JW
    CANCER RESEARCH, 2001, 61 (20) : 7464 - 7472
  • [5] Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer
    Kubo, H
    Gardner, TA
    Wada, Y
    Koeneman, KS
    Gotoh, A
    Yang, L
    Kao, CH
    Lim, SD
    Amin, MB
    Yang, H
    Black, ME
    Matsubara, S
    Nakagawa, M
    Gillenwater, JY
    Zhau, HYE
    Chung, LWK
    HUMAN GENE THERAPY, 2003, 14 (03) : 227 - 241
1